axelvento
2 weeks ago
Melanoma cancer vaccine results “extremely impressive”
The first vaccine treatment for the form of skin cancer usually caused by sun damage could halve the risk of patients dying or the disease returning, according to early trial results.
Researchers led by a team at New York University combined a vaccine using the same mRNA technology as many COVID jabs with an established immunotherapy called pembrolizumab. It was given to patients after they had surgery to remove stage 3 or stage 4 melanoma.
After three years, 75% of those who had the vaccine and pembrolizumab were still cancer-free, compared to 56% of people who only received pembrolizumab.
Iain Foulkes, our executive director of research and innovation explained that the results “show positive signs of the mRNA vaccine’s long-lasting effectiveness”, although larger and longer trials are still needed.
Unlike traditional vaccines, which are used to prevent disease, cancer vaccines are used to treat cancers. The vaccine used in this trial, mRNA-4157 (created by Moderna), is different for every patient. Scientists personalise it to help people’s immune system identify their specific cancer cells. Pembrolizumab, a type of immunotherapy called a checkpoint inhibitor, supports this by effectively taking the brakes off of immune cells called T cells.
Speaking to journalists at ASCO, Swanton called the results “extremely impressive”.
“The new vaccine approach is another piece of the puzzle that will allow more patients to be cured, hopefully, or fewer patients to suffer disease relapse. Ultimately it will contribute to survival rates improving continually over the next decades and more.”
Vexari
3 weeks ago
Japan to ban MRNA
As turbo cancers among vaxxed
Skyrocketing
Turbo cancers are exploding among the vaccinated according to Japan’s leading oncologist who has slammed the mainstream media and Big Pharma in the West for covering up the extent of the medical crisis engulfing the world.
Prof. Emeritus Dr. Masanori Fukushima was ordered by the Japanese government to investigate why excess deaths skyrocketed in Japan in recent years.
His findings were conclusive: mRNA has destroyed immune systems and opened a Pandora’s box of autoimmune diseases, neurodegenerative diseases, cancer, and infections.
The Professor has a dire warning for those in the West – do not listen to mainstream media and Big Pharma as they are not engaged in science, but rather a eugenics experiment, and they have proven themselves to be enemies of the people.
axelvento
3 weeks ago
In a 153-page written ruling on Tuesday, Mr Justice Meade concluded one of the European Moderna patents, labelled EP565, was “invalid”.
But the judge said a different patent, called EP949, was “valid” and was infringed by Pfizer and BioNTech.
A Moderna statement said: “We are pleased that the UK High Court recognised the innovation of Moderna scientists by confirming the validity and infringement of the EP949 patent and that (the) defendants were not entitled to use Moderna’s patented technology for any infringing activity after March 7 2022.
https://www.standard.co.uk/news/crime/pfizer-moderna-high-court-netherlands-germany-b1168104.html
axelvento
4 weeks ago
Carisma Therapeutics Announces Nomination of First In Vivo CAR-M Development Candidate for Hepatocellular Carcinoma Under Collaboration with Moderna
Lin Guey, PhD, Chief Scientific Officer of Therapeutics Research Ventures and Biotherapeutics at Moderna, stated, "We are thrilled with the significant progress we've made in advancing in vivo CAR-M therapies alongside Carisma. We eagerly anticipate further development of the nominated candidate for patients with solid tumors, and we look forward to continued success as we develop additional in vivo CAR-M together to bring new therapies to patients with HCC and other cancers."
The in vivo CAR-M program targeting GPC3 is being developed under the 2022 strategic collaboration agreement between Carisma and Moderna to discover, develop, and commercialize in vivo engineered CAR-M therapeutics for the treatment of cancer. In addition to this program, Moderna has nominated four undisclosed oncology research targets under the collaboration. Carisma is responsible for the discovery and optimization of development candidates, while Moderna will lead the development and commercialization of resulting therapeutics.
https://ir.carismatx.com/news-releases/news-release-details/carisma-therapeutics-announces-nomination-first-vivo-car-m